Suppliers / Nifty Labs

Nifty Labs

India 126 employees Updated 9 July 2026

Nifty Labs is an API manufacturer based in India. It holds 8 valid CEPs across a filed portfolio of 8 molecules. Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 25 September 2025 as VAI.

0
active US DMFs
8
valid CEPs
3
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 25 September 2025 VAI US FDA
  • 22 February 2019 VAI US FDA
  • 27 October 2016 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Hyderabad, India Not on file
NTR, India Not on file
Ntr Dist, India 3007025492

What they file, and where

Molecule Regulators Docs
Esomeprazole EDQM, SFDA (Saudi Arabia) 2
Aripiprazole EDQM 1
Doxazosin Mesilate EDQM 1
Lansoprazole EDQM 1
Quetiapine EDQM 1
Quetiapine Fumarate EDQM 1
Rabeprazole EDQM 1
Rivaroxaban EDQM 1

Also appears on these molecule pages

Apixaban contract manufacturing Cilostazol contract manufacturing Diltiazem contract manufacturing Domperidone contract manufacturing Doxazosin contract manufacturing Duloxetine contract manufacturing Esomeprazole contract manufacturing Itraconazole contract manufacturing Lansoprazole contract manufacturing Olanzapine contract manufacturing Omeprazole contract manufacturing Quetiapine API
Show 1 more molecule pages
Rivaroxaban API

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 1 None
EMA None 1
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Nifty Labs comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 25 September 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates